CJC-1295 — The GHRH Analogue That Amplifies Your Body's Own Growth Hormone Signal

The pituitary gland does not release growth hormone on demand. It releases it in pulses brief, intense bursts triggered by growth hormone-releasing hormone from the hypothalamus, occurring most significantly during deep sleep and in response to exercise and fasting. Between those pulses, GH levels return to baseline and the system resets, ready for the next signal.

This pulsatile architecture is not a limitation of the biology. It is the biology. The feedback systems that prevent excessive GH production, that maintain receptor sensitivity, that allow the pituitary to respond meaningfully to each new signal, all depend on GH being released in pulses rather than continuously. The moments between pulses are not wasted they are essential.

CJC-1295 was designed to work within this architecture rather than around it. As a synthetic analogue of growth hormone-releasing hormone, it binds the GHRH receptor on pituitary somatotrophs and amplifies the natural GH pulse that the hypothalamus is already initiating. It does not produce a continuous GH elevation. It makes each natural pulse bigger, stronger and more sustained, which is a fundamentally different approach from direct GH administration and is part of what gives this compound its distinctive profile.

Understanding the two forms of CJC-1295, with DAC and without DAC, is the most important thing this page can establish clearly because the two versions produce genuinely different physiological effects, suit different protocols and come with different practical considerations. Getting this distinction right is the foundation of using CJC-1295 intelligently.

For those interested in the combination of CJC-1295 with Ipamorelin, the most widely used GH peptide stack, the full combined protocol is covered in detail on the [CJC-1295 with Ipamorelin] page. This page focuses specifically on CJC-1295 as a standalone compound and the DAC versus no-DAC question in full.

What Is CJC-1295?

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone consisting of 29 amino acids. The native GHRH is a 44-amino-acid peptide and the 1-29 fragment retains full biological activity. CJC-1295 starts from this 1-29 backbone with four amino acid substitutions that improve stability and receptor binding affinity relative to the native sequence. WBCIL

It was originally developed by ConjuChem as a clinical drug candidate. Phase 1 and Phase 2 trials showed sustained GH and IGF-1 elevation in healthy adults. Development was discontinued for commercial rather than safety reasons and the pharmacology is well characterised from those trials. This human trial data gives CJC-1295 a more thoroughly characterised clinical profile than many research peptides accumulate through standard investigation alone. The Steele Vault

Two versions of CJC-1295 are available, and the choice between them is not a minor detail. It is a fundamental decision that shapes the entire protocol.

CJC-1295 With DAC vs Without DAC — The Most Important Distinction

CJC-1295 with DAC and without DAC differ in their duration of action and the way they stimulate the GH and IGF-1 axis. In scientific literature they are not considered fully interchangeable peptides. Both target the same hormonal axis — GHRH, GH and IGF-1 but they do so through different temporal dynamics and signalling profiles. PubMed

CJC-1295 Without DAC

Without the DAC modification, CJC-1295 has a half-life of approximately 30 minutes. It binds the GHRH receptor, triggers a GH pulse and is cleared relatively quickly from circulation. This short half-life means it must be dosed more frequently than the DAC version, but it preserves the natural pulsatile pattern of GH release that the biology depends on.

Without DAC, CJC-1295 produces discrete GH pulses similar to natural GHRH-stimulated release. When combined with Ipamorelin, each pulse is amplified. This form is often preferred when combined with a GHRP like Ipamorelin. AutoimmunityCare

CJC-1295 without DAC is also known as Modified GRF 1-29 or Mod GRF, which can cause confusion when reading research or protocol discussions that use these terms interchangeably.

CJC-1295 With DAC

The DAC modification Drug Affinity Complex, adds a maleimide linker that binds covalently to albumin in the bloodstream, dramatically extending the half-life from 30 minutes to approximately 6 to 8 days. This extends the biological activity across most of a week from a single injection, reducing dosing frequency to once or twice weekly.

However, this convenience comes with a significant physiological consideration that is worth understanding clearly. CJC-1295 with DAC creates a continuous low-level elevation of growth hormone rather than natural pulsatile release what researchers describe as a GH bleed rather than a GH pulse. This sustained and constant GH elevation is profoundly unnatural and can lead to pituitary desensitisation and disruption of the delicate hormonal axis over time. Mobile IV Medics

The DAC version produces sustained elevation of baseline GH release rather than pulsatile. Ipamorelin or other GHRPs still trigger discrete pulses on top of this sustained elevation when the two are combined. AutoimmunityCare

The practical conclusion for most research protocols is clear. CJC-1295 without DAC is the preferred form for daily use in combination with Ipamorelin, where the matching half-lives and preserved pulsatile GH release make the combination both physiologically appropriate and practically convenient. CJC-1295 with DAC is used in specific protocols where weekly dosing is the priority and where the sustained GH elevation it produces is understood and accepted as a feature of the approach rather than a concern.

How Does CJC-1295 Work?

CJC-1295 works by binding to GHRH receptors on pituitary somatotroph cells and amplifying the natural growth hormone-releasing signal that the hypothalamus is already sending. It targets the GHRH, GH and IGF-1 axis directly, amplifying the pituitary’s response to the hypothalamic signal rather than bypassing or replacing the natural regulatory system. PubMed

The downstream effects flow through the same pathway as natural GHRH stimulation. Greater GH pulse amplitude leads to greater IGF-1 production in the liver. Elevated IGF-1 drives the tissue-level effects that GH activity is associated with muscle protein synthesis, fat metabolism, cellular repair, collagen production, and the broad spectrum of regenerative effects that optimised GH levels support across the lifespan.

Clinical studies demonstrated that administration leads to sustained elevation of both GH and IGF-1 levels, with effects lasting for several days with the DAC form. An important observation was that despite the prolonged activity, GH pulsatility characteristics were maintained with the non-DAC form. AutoimmunityCare

This preservation of pulsatility with the non-DAC form is what distinguishes CJC-1295 from direct GH administration and is one of the most practically important features of the compound for anyone using it in an ongoing protocol.

What Does the Research Show?

The human research base for CJC-1295 is more developed than for many compounds in this library, largely because of the clinical trial programme that ConjuChem conducted during its pharmaceutical development phase.

Phase 1 and Phase 2 trials in healthy adults demonstrated significant increases in basal and stimulated growth hormone levels. The trials established the pharmacokinetic profile, the dose-response relationship and a favourable tolerability profile. Development was discontinued for commercial rather than safety reasons. The Steele Vault

Clinical studies demonstrate CJC-1295’s efficacy in significant increases in basal and stimulated growth hormone levels, increased lean body mass and muscle protein synthesis, improved insulin sensitivity and glucose metabolism, and enhanced cellular repair mechanisms through restoration of youthful GH and IGF-1 axis function. Burick Center for Health and Wellness

The regulatory position as of April 2026 reflects the broader peptide regulatory landscape. CJC-1295 is listed as Nominated but Withdrawn from Category 2 as of April 22, 2026. This places it in a similar regulatory position to Ipamorelin, where the status remains fluid and subject to ongoing review. The compound is available as a research peptide through the research compound market and is not approved for human therapeutic use in any jurisdiction. Burick Center for Health and Wellness

Who Is CJC-1295 Most Relevant For?

CJC-1295 without DAC is most relevant for anyone seeking to optimise natural GH pulsatility through daily supplementation in combination with Ipamorelin, where the matching half-lives and synergistic receptor activation make the combination both physiologically coherent and practically effective.

CJC-1295 with DAC is more relevant for those whose primary consideration is dosing convenience and who prefer a twice-weekly protocol over daily administration, with an understanding of the sustained rather than pulsatile GH profile it produces.

Both forms are relevant across a wide age range. In younger athletes and active people in their 20s and 30s, CJC-1295 supports the GH-driven recovery and body composition optimisation that serious training demands. In people over 40 experiencing the natural decline in GH production that begins in the mid-twenties, CJC-1295 addresses the underlying hormonal change that contributes to slower recovery, changing body composition and declining sleep quality.

Dosage and Protocol

CJC-1295 Without DAC — Standard Research Protocol:

• Dose: 100 to 200mcg per injection
• Frequency: Once to three times daily. The pre-sleep window is the most commonly prioritised single daily injection point. Twice daily, morning fasted and pre-sleep, is used for more sustained GH elevation
• Timing: Fasted state for maximum GH pulse amplitude. A minimum of two hours without food before injection and 30 minutes after before eating
• Combination: Most commonly combined with Ipamorelin 100 to 200mcg in the same syringe as a single injection. Full combination protocol details on the [CJC-1295 with Ipamorelin] page
• Cycle length: 12 to 16 weeks, followed by a break of 4 to 8 weeks

CJC-1295 With DAC — Standard Research Protocol:

• Dose: 1 to 2mg once or twice weekly
• Frequency: Once or twice per week on consistent days, for example Monday and Thursday
• Timing: Food timing is less critical given the extended half-life, though fasted administration is still generally preferred
• Combination: Can be combined with Ipamorelin or another GHRP on a separate daily schedule the two operate on different timescales and do not need to be injected simultaneously
• Cycle length: 8 to 12 weeks, followed by a break of 4 to 6 weeks

Reconstitution and Mixing Guide

CJC-1295 without DAC typically comes as lyophilised powder in vials of 2mg or 5mg.

Using a 2mg (2,000mcg) vial as the reference:

Add 1ml of bacteriostatic water:

• Concentration = 2,000mcg per ml
• Each unit on a 100-unit insulin syringe = 20mcg
• A 100mcg dose = 5 units
• A 200mcg dose = 10 units

Add 2ml of bacteriostatic water (most commonly used ratio):

• Concentration = 1,000mcg per ml
• Each unit on a 100-unit insulin syringe = 10mcg
• A 100mcg dose = 10 units
• A 200mcg dose = 20 units

Add 0.5ml of bacteriostatic water:

• Concentration = 4,000mcg per ml
• Each unit on a 100-unit insulin syringe = 40mcg
• A 100mcg dose = 2.5 units
• A 200mcg dose = 5 units

For most people adding 2ml to a 2mg vial creates the most practical working concentration with clear and easy unit calculations at both standard dose levels.

CJC-1295 With DAC typically comes in vials of 2mg or 5mg and is reconstituted with a smaller volume of bacteriostatic water given the lower dosing frequency and higher per-injection dose.

Using a 2mg vial for DAC version:

Add 1ml of bacteriostatic water:

• Concentration = 2,000mcg per ml
• Each unit on a 100-unit insulin syringe = 20mcg
• A 1mg (1,000mcg) dose = 50 units
• A 2mg (2,000mcg) dose = 100 units (full syringe)

Reconstitution Method

Inject bacteriostatic water slowly down the inside wall of the vial rather than directly onto the powder. Gently swirl rather than shake until fully dissolved. The solution should be clear and colourless.

Storage

Reconstituted CJC-1295 should be refrigerated at 2 to 8 degrees Celsius and used within 28 to 30 days. Do not freeze a reconstituted vial. Lyophilised powder should be refrigerated away from light and moisture until reconstituted.

Supporting Supplements

The supplements that most coherently support CJC-1295 are those that complement the GHRH-driven GH axis it activates and the body composition, recovery and sleep goals it is most commonly used to support.

Zinc and Magnesium are the most directly relevant. Zinc supports GH synthesis and IGF-1 signalling. Magnesium supports deep sleep quality in which the overnight GH pulse CJC-1295 amplifies is most significant.

Vitamin D maintains the hormonal and metabolic environment in which GH activity produces the most meaningful results, with particular relevance to the IGF-1 signalling that downstream GH activity drives.

Protein at adequate daily intake provides the amino acids that elevated IGF-1 activity will use for tissue repair and lean tissue development. A target of 1.6 to 2g per kilogram of bodyweight daily supports the anabolic signalling that CJC-1295 amplifies.

Collagen peptides with Vitamin C taken before sleep complement the pre-sleep CJC-1295 protocol by providing the structural building blocks for the connective tissue repair that elevated GH activity during the overnight window supports.

Omega-3 fatty acids support the anti-inflammatory environment in which recovery and body composition improvement occur most effectively.

Foods That Complement CJC-1295

The most important nutritional consideration for CJC-1295 without DAC mirrors Ipamorelin exactly: the fasted window around each injection is the critical variable that determines how effectively the compound amplifies the natural GH pulse.

Food intake close to injection time elevates insulin, which directly blunts GH release. A clean fast of at least two hours before injection and 30 minutes after is the standard approach that preserves the maximum GH pulse amplitude. For the pre-sleep window, this means finishing the evening meal well before the injection and avoiding late evening snacking entirely.

Through the rest of the day lean protein at every meal, healthy fats, complex carbohydrates and an anti-inflammatory food base create the metabolic environment in which GH and IGF-1 activity translates most effectively into the body composition and recovery improvements that CJC-1295 is used to support.

Alcohol directly impairs GH release, disrupts slow-wave sleep architecture and elevates cortisol, working against all three of the primary outcomes that a CJC-1295 protocol is designed to deliver.

Lifestyle Considerations

Sleep quality is the lifestyle factor of highest importance for anyone using CJC-1295 in a pre-sleep protocol. The overnight GH pulse that CJC-1295 amplifies is the most significant natural GH release of the entire 24-hour cycle, occurring primarily during slow-wave sleep. Protecting sleep duration and architecture throughout the cycle extracts the maximum value from the compound’s mechanism and is one of the most impactful actions available to anyone running this protocol.

Resistance training creates the exercise-induced GH stimulus that CJC-1295 amplifies most productively. The combination of the training-driven hypothalamic GHRH signal and CJC-1295’s amplification of the pituitary response produces a more substantial combined GH release than the training stimulus alone generates.

Stress management — chronic cortisol elevation directly antagonises GH signalling at the hypothalamic and pituitary level. Managing chronic stress is not a peripheral consideration for anyone using CJC-1295 but a genuine component of getting meaningful results from the protocol.

Consistency is particularly important with CJC-1295 without DAC given its daily administration requirement. The cumulative benefits of consistently amplified daily GH pulses over a 12 to 16 week cycle are what produce the body composition, recovery and sleep improvements the compound is used for. Missing doses breaks the consistency that the cumulative benefit depends on.

Peptide Pairing

Ipamorelin is the most natural, most widely used and most evidence-supported pairing with CJC-1295 without DAC. The GHRH receptor activation of CJC-1295 and the ghrelin receptor activation of Ipamorelin produce a synergistic GH pulse significantly greater than either generates independently. The full combined protocol, including reconstitution of both compounds and administration as a single injection, is covered in detail on the [CJC-1295 with Ipamorelin] page.

BPC-157 pairs coherently with CJC-1295 for the active person who wants both GH axis optimisation and tissue repair support. BPC-157 addresses localised tissue repair during the day while CJC-1295 drives the overnight GH regeneration phase.

TB-500 similarly complements CJC-1295 by providing systemic tissue repair support alongside the GH-driven overnight recovery the compound amplifies.

IGF-1 LR3 is used alongside CJC-1295 in more advanced protocols, with CJC-1295 driving the upstream GHRH stimulus and IGF-1 LR3 providing direct downstream IGF-1 receptor activation on training days.

Realistic Expectations

CJC-1295 is one of the most thoroughly characterised GH peptides available, with human clinical trial data from its pharmaceutical development programme and decades of research community use providing a well-established profile of its effects and tolerability.

The improvements most consistently reported include meaningful improvements in sleep quality within the first two to four weeks, enhanced recovery from training as IGF-1 levels increase across the cycle, progressive improvements in body composition including reduced body fat and improved lean tissue over a 12 to 16 week protocol, and the broader spectrum of effects associated with optimised GH levels including improved skin quality, joint health and sustained energy.

The DAC versus no-DAC choice shapes which of those benefits is most prominent and how the protocol is managed day to day. CJC-1295 without DAC produces the most physiologically natural GH amplification and is the most appropriate form for most research protocols. CJC-1295 with DAC offers convenience at the cost of the pulsatile GH pattern that the body’s own regulatory systems are designed to work within.

Used consistently, at appropriate doses, with fasted injection timing for the non-DAC form, the sleep and resistance training support that GH activity amplifies most effectively, and the nutritional foundation described above CJC-1295 delivers on its position as one of the most well-evidenced and most widely trusted growth hormone peptides in the research community.